TW202116801A - 抗tau抗體及其用途 - Google Patents

抗tau抗體及其用途 Download PDF

Info

Publication number
TW202116801A
TW202116801A TW109123934A TW109123934A TW202116801A TW 202116801 A TW202116801 A TW 202116801A TW 109123934 A TW109123934 A TW 109123934A TW 109123934 A TW109123934 A TW 109123934A TW 202116801 A TW202116801 A TW 202116801A
Authority
TW
Taiwan
Prior art keywords
antibody
tau
seq
amino acid
acid sequence
Prior art date
Application number
TW109123934A
Other languages
English (en)
Chinese (zh)
Inventor
尹丞鏞
Original Assignee
南韓商愛黛兒公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 南韓商愛黛兒公司 filed Critical 南韓商愛黛兒公司
Publication of TW202116801A publication Critical patent/TW202116801A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
TW109123934A 2019-07-15 2020-07-15 抗tau抗體及其用途 TW202116801A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2019-0085233 2019-07-15
KR20190085233 2019-07-15

Publications (1)

Publication Number Publication Date
TW202116801A true TW202116801A (zh) 2021-05-01

Family

ID=74088428

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109123934A TW202116801A (zh) 2019-07-15 2020-07-15 抗tau抗體及其用途

Country Status (16)

Country Link
US (1) US20220204601A1 (https=)
EP (1) EP4001305A4 (https=)
JP (1) JP7595061B2 (https=)
KR (1) KR102196840B1 (https=)
CN (1) CN114430744B (https=)
AU (1) AU2020313751A1 (https=)
BR (1) BR112022000719A2 (https=)
CA (1) CA3143811A1 (https=)
CL (1) CL2022000087A1 (https=)
GB (1) GB2600599B (https=)
IL (1) IL289813A (https=)
MX (1) MX2022000603A (https=)
MY (1) MY207132A (https=)
PH (1) PH12022550106A1 (https=)
TW (1) TW202116801A (https=)
WO (1) WO2021010712A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10501531B2 (en) 2013-03-13 2019-12-10 Prothena Biosciences Limited Tau immunotherapy
MY198194A (en) 2016-05-02 2023-08-09 Prothena Biosciences Ltd Antibodies Recognizing Tau
PT3452507T (pt) 2016-05-02 2022-12-20 Prothena Biosciences Ltd Imunoterapia anti-tau
KR102784294B1 (ko) 2017-05-02 2025-03-19 프로테나 바이오사이언시즈 리미티드 타우 인식 항체
JP7630834B2 (ja) 2019-03-03 2025-02-18 プロセナ バイオサイエンシーズ リミテッド タウ認識抗体
US20240376188A1 (en) * 2021-09-09 2024-11-14 The University Of North Carolina At Chapel Hill Monoclonal antibodies targeting acetylated tau and methods of use thereof
US20250134952A1 (en) 2021-09-20 2025-05-01 Institut National de la Santé et de la Recherche Médicale Methods for improving the efficacy of hdac inhibitor therapy and predicting the response to treatment with hdac inhibitor
WO2023229445A1 (ko) * 2022-05-27 2023-11-30 주식회사 진큐어 신규 펩타이드 및 그의 용도
CN115724967A (zh) * 2022-09-21 2023-03-03 天津鸿宇泰生物科技有限公司 一种识别Tau蛋白N端区域的单克隆抗体及其应用
EP4631975A1 (en) 2022-12-08 2025-10-15 Adel Inc. Fusion comprising anti-tau antibody and peptide and use thereof
WO2024133723A1 (en) 2022-12-22 2024-06-27 Institut National de la Santé et de la Recherche Médicale Methods for decreasing therapeutic acquired resistance to chemotherapy and/or radiotherapy
CN116716352A (zh) * 2023-05-16 2023-09-08 深圳湾实验室 Tau蛋白聚集的细胞模型、其构建方法及应用
CN116693682B (zh) * 2023-06-02 2024-04-19 涌源合生科技(深圳)有限公司 抗Tau蛋白抗体及其制备方法和用途
CN116948025B (zh) * 2023-09-14 2024-04-02 北京凯祥弘康生物科技有限公司 一种抗Tau蛋白的抗体

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130251731A1 (en) * 2012-03-22 2013-09-26 The Trustees Of The University Of Pennsylvania Tau Acetylation in the Pathogenesis of Alzheimers Disease and Other Related Tauopathies
RU2644242C2 (ru) * 2012-04-05 2018-02-08 Ац Иммуне С.А. Гуманизированное тау-антитело
SG10201708959WA (en) 2012-07-03 2017-11-29 Univ Washington Antibodies to tau
TWI734975B (zh) * 2014-06-27 2021-08-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗-tau抗體
TWI669314B (zh) * 2015-02-26 2019-08-21 美國禮來大藥廠 針對ｔａｕ之抗體及其用途
WO2018106889A1 (en) * 2016-12-09 2018-06-14 Cogwellin L.L.C. Diagnosis of alzheimer's disease
KR102032314B1 (ko) * 2016-12-21 2019-10-16 주식회사 아델 변이된 타우 단백질 단편 및 이의 용도

Also Published As

Publication number Publication date
CL2022000087A1 (es) 2023-03-10
GB2600599B (en) 2025-05-21
MY207132A (en) 2025-01-31
AU2020313751A1 (en) 2022-02-10
EP4001305A1 (en) 2022-05-25
MX2022000603A (es) 2022-05-20
CN114430744A (zh) 2022-05-03
CN114430744B (zh) 2024-06-21
BR112022000719A2 (pt) 2022-03-29
EP4001305A9 (en) 2023-05-24
EP4001305A4 (en) 2022-10-12
GB2600599A8 (en) 2024-12-25
CA3143811A1 (en) 2021-01-21
PH12022550106A1 (en) 2022-11-21
IL289813A (en) 2022-03-01
JP2022541539A (ja) 2022-09-26
WO2021010712A1 (ko) 2021-01-21
KR102196840B1 (ko) 2020-12-30
JP7595061B2 (ja) 2024-12-05
GB2600599A (en) 2022-05-04
US20220204601A1 (en) 2022-06-30
GB202201160D0 (en) 2022-03-16

Similar Documents

Publication Publication Date Title
US20220204601A1 (en) Anti-tau antibody and use of same
KR101505201B1 (ko) 치료적 특성을 갖는 베타 1-42 특이적인 단일클론성 항체
JP6620829B2 (ja) 認知症治療剤又は予防剤
EP3160999B1 (en) Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
KR101600095B1 (ko) 모노클로널 항 베타 아밀로이드 항체
KR101831459B1 (ko) 올리고머 특이적 아밀로이드 베타 에피토프 및 항체
JP6884025B2 (ja) アルツハイマ病の治療および診断方法における使用のためのＮ末端切断型アミロイドβプロトフィブリル／オリゴマ
JP6976943B2 (ja) 抗補体因子Ｃ１ｑ Ｆａｂ断片及びその使用
RU2604181C2 (ru) Применение антитела против амилоида бета при глазных заболеваниях
JP2018139530A (ja) 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤
CN113490505A (zh) 用于治疗tau蛋白病的tau肽抗原及与其结合的抗体
JP2023554382A (ja) タウ結合化合物
CN118647405A (zh) 改善认知障碍的方法
WO2022201123A1 (en) Anti-tau antibodies and uses thereof
US11434281B2 (en) Monoclonal antibodies targeting PHF1 and AT8 epitopes of human tau protein
KR102032314B1 (ko) 변이된 타우 단백질 단편 및 이의 용도
US20240358805A1 (en) Methods and materials to treat neurodegenerative disease
EA047253B1 (ru) Антитело к тау-белку и его применение